Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/15/2021 09/16/2021 09/17/2021 09/20/2021 09/21/2021 Date
34.11(c) 33.78(c) 34.8(c) 33.36(c) 35.01(c) Last
189 490 221 162 1 925 907 213 835 179 514 Volume
-2.29% -0.97% +3.02% -4.14% +4.95% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 16,9 M - -
Net income 2021 -71,0 M - -
Net cash position 2021 196 M - -
P/E ratio 2021 -13,4x
Yield 2021 -
Sales 2022 5,55 M - -
Net income 2022 -93,1 M - -
Net cash position 2022 79,7 M - -
P/E ratio 2022 -11,9x
Yield 2022 -
Capitalization 945 M 945 M -
EV / Sales 2021 44,2x
EV / Sales 2022 156x
Nbr of Employees 104
Free-Float 76,9%
More Financials
Company
4D Molecular Therapeutics, Inc. is a clinical-stage stage gene therapy company. The Company is focused on developing targeted therapies based on its adeno-associated viruses (AAV) vectors. It uses its Therapeutic Vector Evolution platform to customize its AAV vectors to target specific tissue types associated with the disease. The Company is focuses on three therapeutic areas: ophthalmology (intravitreal vector),... 
More about the company
Ratings of 4D Molecular Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about 4D MOLECULAR THERAPEUTICS, INC.
08/124D MOLECULAR THERAPEUTICS : Reports Financial Results for the Second Quarter of 2021 and P..
PU
08/124D MOLECULAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition an..
AQ
08/124D MOLECULAR THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial ..
AQ
08/124D MOLECULAR THERAPEUTICS : Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS Reports Q2 Rev..
MT
08/124D MOLECULAR THERAPEUTICS : Reports Financial Results for the Second Quarter of 2021 and P..
AQ
08/124D Molecular Therapeutics, Inc. Announces Unaudited Earnings Results for the Second Qua..
CI
08/124D Molecular Therapeutics, Inc. Appoints Nadine Greiner as Chief Human Resources Office..
CI
06/254D MOLECULAR THERAPEUTICS INC. : Termination of a Material Definitive Agreement, Other Eve..
AQ
06/254D Molecular Therapeutics, Inc. Announces Rare Disease Ophthalmology Product Candidate ..
CI
06/254D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000E Growth Index
CI
06/254D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell Microcap Growth Index
CI
06/254D-110 : Initial clinical safety data at both of the two dose levels in the Phase 1 clinic..
PU
06/254D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell Microcap Index
CI
06/254D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000E Index
CI
06/254D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000E Value Index
CI
More news
News in other languages on 4D MOLECULAR THERAPEUTICS, INC.

- No features available -

More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | FDMT | US35104E1001 | MarketScreener
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 35,01 $
Average target price 50,00 $
Spread / Average Target 42,8%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Operating & Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-15.54%945
MODERNA, INC.315.47%170 876
LONZA GROUP AG31.58%59 927
IQVIA HOLDINGS INC.43.03%48 510
CELLTRION, INC.-23.26%31 691
SEAGEN INC.-5.78%28 939